Navigation Links
Cancer signatures uncovered
Date:8/15/2008

A new systematic analysis of the relationship between the neoplastic and developmental transcriptome provides an outline of trends in cancer gene expression. The research, published recently in BioMed Central's open access journal Genome Biology, describes how cancers can be divided into three groups distinguished by disparate developmental signatures.

Isaac S Kohane from Children's Hospital Boston and Harvard University, US, led a team of researchers who performed a comprehensive comparison of genes expressed in early developmental stages of various human tissues and those expressed in different cancers affecting these tissues. He says, "Our study reveals potentially clinically relevant differences in the gene expression of different cancer types and represents a reference framework for interpretation of smaller-scale functional studies".

One of the three described groups of cancers has an early developmental phenotype and expresses genes that are characteristic of stem cells. From a developmental perspective, this group presents very homogeneously. A second, more heterogeneous group tends to be more similar to late development and is characterized by an inflammatory signature. The third is a small group of cancers that present as a transition phenotype between these two extremes and displays both characteristics.

According to Kohane, "This segregation of tumors into three groups with distinct expression patterns is surprising. Clearly, the developmental trajectory provides a meaningful background for capturing large-scale differences in gene expression across diverse conditions".

The study's results will lead towards a better understanding of human disease from a 'macrobiological' approach to analyzing high-throughput data. According to the authors, "Shifting our focus from single sets of genes or processes to the biology of aggregates on the order of the entire transcriptome is likely to be useful in establishing highly robust molecular correlations between seemingly unrelated disease phenotypes".


'/>"/>
Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-707-94804
BioMed Central
Source:Eurekalert

Related biology news :

1. Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
2. Scientists discover major genetic cause of colorectal cancer
3. Commercialization aim of grant supporting technology that destroys cancer cells
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. Monash researchers uncover cancer survival secrets
6. Researchers find cancer-inhibiting compound under the sea
7. Pre-cancerous condition linked to chronic acid reflux faces several hurdles
8. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
9. Cold Spring Harbor Protocols highlights gene silencing, cancer cell biology methods
10. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
11. A new cellular pathway linked to cancer is identified by NYU researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology: